Prolactinoma

What changes during this transition

Prolactinoma is the editorially distinct pituitary adenoma. Where every other pituitary tumor (acromegaly, Cushing's disease, non-functioning macroadenomas) defaults to transsphenoidal surgery as first-line, prolactinoma inverts the algorithm: dopamine agonists are first-line for nearly all patients, and surgery is reserved for medication-resistant (~10-20%) or intolerant cases or apoplexy. This inversion exists because lactotrophs are exquisitely sensitive to D2 dopamine receptor agonism — both PRL secretion and tumor cell proliferation respond. Cabergoline (twice-weekly oral, longer half-life, better tolerated) shrinks 80-90% of macroprolactinomas and normalizes PRL in most patients. Bromocriptine (multiple daily dosing, more GI side effects) remains relevant primarily for pregnancy planning where its decades-long registry safety record favors it; quinagolide / Norprolac is a non-ergot DA available in the EU and other jurisdictions but not FDA-approved in the US. The 2011 Endocrine Society clinical practice guideline and 2024 update both position DA therapy as first-line ahead of surgery for prolactinoma — UNIQUE among pituitary adenomas. The substrate framing for prolactinoma centers on the load-bearing causal chain. PRL acts at the hypothalamus to suppress GnRH pulsatility; suppressed GnRH causes downstream collapse of LH and FSH pulsatility; without normal gonadotropin support, gonadal steroidogenesis falls. In women, this manifests as anovulation, hypoestrogenism, and the menstrual irregularities. In men, it manifests as secondary hypogonadism with low testosterone in the face of inappropriately normal or low LH / FSH. The clinically important implication: the hypogonadism is driven by upstream PRL excess, not by a primary defect in the gonadotropin axis. When PRL normalizes on dopamine agonist therapy, the HPG axis recovers spontaneously in most patients. This is why the kisspeptin and gonadorelin substrate entries land on the same critique — the load-bearing intervention is PRL suppression at the source, not GnRH or kisspeptin stimulation against a still-suppressed hypothalamus. The community framing that 'kisspeptin restarts what PRL shut down' inverts the causal chain: kisspeptin tries to push GnRH against an active brake. The diagnostic workup discipline matters in this disease, because the differential is broad and each entry has its own management. Morning fasting prolactin above 200 ng/mL is strongly suggestive of prolactinoma; 25-200 ng/mL requires differential workup before assuming prolactinoma. The differential: pregnancy (beta-hCG before pituitary imaging in any woman of reproductive age), medication-induced hyperprolactinemia (antipsychotics are the largest category — risperidone especially; also haloperidol, metoclopramide, verapamil, opioids, estrogen, SSRIs to a lesser degree), primary hypothyroidism (elevated TRH cross-stimulates lactotrophs — TSH is non-negotiable), macroprolactin (biologically inactive PRL-IgG complex inflates the assay number without causing the syndrome — measured by polyethylene glycol precipitation; treating macroprolactin as prolactinoma is treating an artifact), and stalk effect (large non-functioning adenomas can disrupt the tonic dopamine inhibition of lactotrophs and produce moderate hyperprolactinemia). Pituitary MRI characterizes the lesion; macroadenomas warrant visual field testing for chiasmal compression and a full anterior pituitary panel for hypopituitarism. The substrate editorial entries all fail on the same load-bearing fact pattern. Kisspeptin and gonadorelin push GnRH against an actively-PRL-suppressed hypothalamus — the suppression resolves when PRL normalizes on cabergoline, making upstream stimulation unnecessary and mechanically the wrong direction. BPC-157 has no characterization in pituitary adenoma biology, and its angiogenic profile is a theoretical concern in any tumor-bearing tissue. NMN extends general-aging framing into a disease context where the downstream consequences (bone density, cardiovascular, metabolic) are best resolved by treating the underlying hypogonadism via PRL normalization. CJC-1295 and ipamorelin act on the same organ that bears the tumor — sustained pituitary stimulation in an adenoma-bearing gland is uncharacterized, and the wellness-clinic offer does not engage with the load-bearing concern. None of these rise to the bar of editorial elevation; the substrate exists to honor the questions users will bring to /ask while keeping the load-bearing answer load-bearing. This is the 54th deliberate non-elevation. Resources: Pituitary Network Association, American Association of Neurological Surgeons (AANS), Endocrine Society guidelines.